Brief: Heidelberg Pharma: Magenta Therapeutics To Further Develop Antibody Targeted Amanitin Conjugates
11/11/2019 13:52
Nov 11 (Reuters) - HEIDELBERG PHARMA AG WL6G.DE :
* HEIDELBERG PHARMA AG: PARTNER MAGENTA THERAPEUTICS
EXERCISES
OPTION TO FURTHER DEVELOP ANTIBODY TARGETED AMANITIN CONJUGATES
TARGETED TO CD45
* HEIDELBERG PHARMA RECEIVES AN UNDISCLOSED MILESTONE
PAYMENT IN
RETURN
Source text for Eikon: ID:nEQ84Rb29a
Further company coverage: WL6G.DE
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on Heidelberg Pharma AG
See all newsBrief: Heidelberg Pharma And Huadong Medicine Receive Nmpa Approval For Hdp-101 Trial In China
Germany's Heidelberg Pharma H1 sales revenue surges, driven by milestone payments
Brief: Heidelberg Pharma Says Co. And Healthcare Royalty Announce Amendment To Existing Royalty Agreement
Brief: Redhill Biopharma Secures Allowance Of Key Chinese Patent Application For Proprietary COVID-19 Treatment, RHB-107
Brief: Heidelberg Pharma Amends Royalty Financing With Healthcare Royalty